{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:10:07Z","timestamp":1790363407982,"version":"4.1.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The National Science Centre","award":["2016\/21\/B\/NZ7\/01079"],"award-info":[{"award-number":["2016\/21\/B\/NZ7\/01079"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13496-0","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:47:58Z","timestamp":1758883678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Telomerase inhibitors TMPyP4 and BIBR 1532 show synergistic antitumor activity in combination with chemotherapeutic drugs"],"prefix":"10.1038","volume":"15","author":[{"given":"Aleksandra","family":"Romaniuk-Drapa\u0142a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Toto\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Lisiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Idzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u0142a\u017cej","family":"Rubi\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"13496_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA. Cancer J. Clin."},{"key":"13496_CR2","unstructured":"Global health estimates: Leading causes of death. https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates\/ghe-leading-causes-of-death."},{"key":"13496_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.265","volume":"4","author":"Z Lei","year":"2023","unstructured":"Lei, Z. et al. Understanding and targeting resistance mechanisms in cancer. MedComm 4, e265 (2023).","journal-title":"MedComm"},{"key":"13496_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1152\/physrev.00024.2015","volume":"96","author":"A Wicki","year":"2016","unstructured":"Wicki, A. et al. Acquired resistance to clinical cancer therapy: A Twist in physiological signaling. Physiol. Rev. 96, 805\u2013829 (2016).","journal-title":"Physiol. Rev."},{"key":"13496_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.semcancer.2011.10.001","volume":"21","author":"JW Shay","year":"2011","unstructured":"Shay, J. W. & Wright, W. E. Role of telomeres and telomerase in cancer. Semin. Cancer Biol. 21, 349\u2013353 (2011).","journal-title":"Semin. Cancer Biol."},{"key":"13496_CR6","doi-asserted-by":"publisher","unstructured":"von Zglinicki, T., Saretzki, G. & Passos, J. Aging and Telomeres. in Reference Module in Biomedical Sciences (Elsevier). https:\/\/doi.org\/10.1016\/B978-0-12-801238-3.00018-0. (2014)","DOI":"10.1016\/B978-0-12-801238-3.00018-0"},{"key":"13496_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009132","volume":"5","author":"O Uziel","year":"2010","unstructured":"Uziel, O. et al. Telomere shortening sensitizes cancer cells to selected cytotoxic agents: In vitro and in vivo studies and putative mechanisms. PLOS ONE 5, e9132 (2010).","journal-title":"PLOS ONE"},{"key":"13496_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13073-016-0324-x","volume":"8","author":"MA Jafri","year":"2016","unstructured":"Jafri, M. A., Ansari, S. A., Alqahtani, M. H. & Shay, J. W. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 8, 69 (2016).","journal-title":"Genome Med."},{"key":"13496_CR9","first-page":"320","volume":"1866","author":"NJ Robinson","year":"2016","unstructured":"Robinson, N. J. & Schiemann, W. P. Means to the ends: The role of telomeres and telomere processing machinery in metastasis. Biochim. Biophys. Acta 1866, 320\u2013329 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"13496_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/ijms19020606","volume":"19","author":"M De Vitis","year":"2018","unstructured":"De Vitis, M., Berardinelli, F. & Sgura, A. Telomere length maintenance in cancer: At the crossroad between telomerase and alternative lengthening of telomeres (ALT). Int. J. Mol. Sci. 19, 606 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"13496_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cancergen.2013.10.001","volume":"206","author":"A Queisser","year":"2013","unstructured":"Queisser, A., Heeg, S., Thaler, M., von Werder, A. & Opitz, O. G. Inhibition of telomerase induces alternative lengthening of telomeres during human esophageal carcinogenesis. Cancer Genet. 206, 374\u2013386 (2013).","journal-title":"Cancer Genet."},{"key":"13496_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/cells10040867","volume":"10","author":"A Romaniuk-Drapa\u0142a","year":"2021","unstructured":"Romaniuk-Drapa\u0142a, A. et al. hTERT downregulation attenuates resistance to DOX, Impairs FAK-mediated adhesion, and leads to autophagy induction in breast cancer cells. Cells 10, 867 (2021).","journal-title":"Cells"},{"key":"13496_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100110","volume":"3","author":"D Duarte","year":"2022","unstructured":"Duarte, D. & Vale, N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr. Res. Pharmacol. Drug Discov. 3, 100110 (2022).","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"13496_CR14","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.7150\/jca.32205","volume":"10","author":"LM Hess","year":"2019","unstructured":"Hess, L. M., Brnabic, A., Mason, O., Lee, P. & Barker, S. Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology. J. Cancer 10, 3717\u20133727 (2019).","journal-title":"J. Cancer"},{"key":"13496_CR15","unstructured":"Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2 null (2019)."},{"key":"13496_CR16","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.3390\/ijms20112670","volume":"20","author":"N Konieczna","year":"2019","unstructured":"Konieczna, N. et al. Telomerase inhibitor TMPyP4 alters adhesion and migration of breast-cancer cells MCF7 and MDA-MB-231. Int. J. Mol. Sci. 20, 2670 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"13496_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/v13020196","volume":"13","author":"S Artusi","year":"2021","unstructured":"Artusi, S. et al. Antiviral activity of the G-Quadruplex ligand TMPyP4 against herpes simplex virus-1. Viruses 13, 196 (2021).","journal-title":"Viruses"},{"key":"13496_CR18","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/jor.21451","volume":"29","author":"J Fujimori","year":"2011","unstructured":"Fujimori, J. et al. Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. J. Orthop. Res. 29, 1707\u20131711 (2011).","journal-title":"J. Orthop. Res."},{"key":"13496_CR19","doi-asserted-by":"publisher","first-page":"26592","DOI":"10.1038\/srep26592","volume":"6","author":"X-H Zheng","year":"2016","unstructured":"Zheng, X.-H. et al. TMPyP4 promotes cancer cell migration at low doses, but induces cell death at high doses. Sci. Rep. 6, 26592 (2016).","journal-title":"Sci. Rep."},{"key":"13496_CR20","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/j.1751-1097.2009.00600.x","volume":"85","author":"S Tada-Oikawa","year":"2009","unstructured":"Tada-Oikawa, S., Oikawa, S., Hirayama, J., Hirakawa, K. & Kawanishi, S. DNA damage and apoptosis induced by photosensitization of 5,10,15,20-Tetrakis (N-methyl-4-pyridyl)-21H,23H-porphyrin via singlet oxygen generation. Photochem. Photobiol. 85, 1391\u20131399 (2009).","journal-title":"Photochem. Photobiol."},{"key":"13496_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1021\/bc9800872","volume":"10","author":"S Mettath","year":"1999","unstructured":"Mettath, S., Munson, B. R. & Pandey, R. K. DNA interaction and photocleavage properties of porphyrins containing cationic substituents at the peripheral position. Bioconjug. Chem. 10, 94\u2013102 (1999).","journal-title":"Bioconjug. Chem."},{"key":"13496_CR22","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/pharmaceutics15041194","volume":"15","author":"M Balas","year":"2023","unstructured":"Balas, M. et al. Photodynamic activity of TMPyP4\/TiO2 complex under blue light in human melanoma cells: potential for cancer-selective therapy. Pharmaceutics 15, 1194 (2023).","journal-title":"Pharmaceutics"},{"key":"13496_CR23","first-page":"620776","volume":"7","author":"G Altamura","year":"2021","unstructured":"Altamura, G. et al. The small molecule BIBR1532 exerts potential anti-cancer activities in preclinical models of feline oral squamous cell carcinoma through inhibition of telomerase activity and down-regulation of TERT front. Vet. Sci. 7, 620776 (2021).","journal-title":"Vet. Sci."},{"key":"13496_CR24","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.7150\/jca.13054","volume":"6","author":"W Kong","year":"2015","unstructured":"Kong, W. et al. Knockdown of hTERT and treatment with BIBR1532 inhibit cell proliferation and invasion in endometrial cancer cells. J. Cancer 6, 1337\u20131345 (2015).","journal-title":"J. Cancer"},{"key":"13496_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118060","volume":"257","author":"A Nasrollahzadeh","year":"2020","unstructured":"Nasrollahzadeh, A. et al. Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-\u03baB signaling pathway. Life Sci. 257, 118060 (2020).","journal-title":"Life Sci."},{"key":"13496_CR26","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2174\/18715206113139990126","volume":"13","author":"D Bashash","year":"2013","unstructured":"Bashash, D. et al. BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: Therapeutic potential for APL. Anticancer Agents Med. Chem. 13, 1115\u20131125 (2013).","journal-title":"Anticancer Agents Med. Chem."},{"key":"13496_CR27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ijrobp.2019.08.009","volume":"105","author":"X Ding","year":"2019","unstructured":"Ding, X. et al. BIBR1532, a selective telomerase inhibitor, enhances radiosensitivity of non-small cell lung cancer through increasing telomere dysfunction and ATM\/CHK1 inhibition. Int. J. Radiat. Oncol. Biol. Phys. 105, 861\u2013874 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"13496_CR28","unstructured":"Types of Chemotherapy Drugs | SEER Training. https:\/\/training.seer.cancer.gov\/treatment\/chemotherapy\/types.html."},{"key":"13496_CR29","unstructured":"Amjad, M. T., Chidharla, A. & Kasi, A. Cancer chemotherapy. In StatPearls (StatPearls Publishing, Treasure Island (FL), (2024)."},{"issue":"364","key":"13496_CR30","first-page":"378","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari, S., Bernard, P. & Tchounwou,. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J. Pharmacol. 740(364), 378 (2014).","journal-title":"Eur J. Pharmacol."},{"key":"13496_CR31","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/201367","volume":"2010","author":"A Basu","year":"2010","unstructured":"Basu, A. & Krishnamurthy, S. Cellular responses to cisplatin-induced DNA damage. J. Nucleic Acids 2010, 201367 (2010).","journal-title":"J. Nucleic Acids"},{"key":"13496_CR32","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1126\/science.1072682","volume":"298","author":"GL Johnson","year":"2002","unstructured":"Johnson, G. L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911\u20131912 (2002).","journal-title":"Science"},{"key":"13496_CR33","doi-asserted-by":"publisher","first-page":"1103062","DOI":"10.3389\/fphar.2023.1103062","volume":"14","author":"N Alassaf","year":"2023","unstructured":"Alassaf, N. & Attia, H. Autophagy and necroptosis in cisplatin-induced acute kidney injury: Recent advances regarding their role and therapeutic potential. Front Pharmacol. 14, 1103062 (2023).","journal-title":"Front Pharmacol."},{"key":"13496_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/ijc.21242","volume":"117","author":"LL Belyanskaya","year":"2005","unstructured":"Belyanskaya, L. L. et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int. J. Cancer 117, 755\u2013763 (2005).","journal-title":"Int. J. Cancer"},{"key":"13496_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.15252\/emmm.201607062","volume":"9","author":"J Nonnekens","year":"2017","unstructured":"Nonnekens, J. & Hoeijmakers, J. H. After surviving cancer, what about late life effects of the cure?. EMBO Mol. Med. 9, 4\u20136 (2017).","journal-title":"EMBO Mol. Med."},{"key":"13496_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.102925","volume":"88","author":"S Ghosh","year":"2019","unstructured":"Ghosh, S. Cisplatin: The first metal based anticancer drug. Bioorganic Chem. 88, 102925 (2019).","journal-title":"Bioorganic Chem."},{"key":"13496_CR37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn, C. F. et al. Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet. Genomics 21, 440\u2013446 (2011).","journal-title":"Pharmacogenet. Genomics"},{"key":"13496_CR38","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/cells12040659","volume":"12","author":"M Kciuk","year":"2023","unstructured":"Kciuk, M. et al. Doxorubicin\u2014An agent with multiple mechanisms of anticancer activity. Cells 12, 659 (2023).","journal-title":"Cells"},{"key":"13496_CR39","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1021\/bc4005427","volume":"25","author":"CH Stuart","year":"2014","unstructured":"Stuart, C. H. et al. Site-specific DNA\u2013doxorubicin conjugates display enhanced cytotoxicity to breast cancer cells. Bioconjug. Chem. 25, 406\u2013413 (2014).","journal-title":"Bioconjug. Chem."},{"key":"13496_CR40","first-page":"84","volume":"1845","author":"F Yang","year":"2014","unstructured":"Yang, F., Teves, S. S., Kemp, C. J. & Henikoff, S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim. Biophys. Acta 1845, 84\u201389 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"13496_CR41","doi-asserted-by":"publisher","first-page":"760","DOI":"10.7150\/ijbs.65258","volume":"18","author":"C-Y Kong","year":"2022","unstructured":"Kong, C.-Y. et al. Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: Oxidative stress and cell death. Int. J. Biol. Sci. 18, 760\u2013770 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"13496_CR42","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3892\/ijo.2016.3558","volume":"49","author":"N Pilco-Ferreto","year":"2016","unstructured":"Pilco-Ferreto, N. & Calaf, G. M. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int. J. Oncol. 49, 753\u2013762 (2016).","journal-title":"Int. J. Oncol."},{"key":"13496_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/sj.cdd.4400793","volume":"8","author":"O Cuvillier","year":"2001","unstructured":"Cuvillier, O. et al. Sphingosine generation, cytochrome c release, and activation of caspase-7 in doxorubicin-induced apoptosis of MCF7 breast adenocarcinoma cells. Cell Death Differ. 8, 162\u2013171 (2001).","journal-title":"Cell Death Differ."},{"key":"13496_CR44","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s12640-023-00652-5","volume":"41","author":"K Kami\u0144ska","year":"2023","unstructured":"Kami\u0144ska, K. & Cudnoch-J\u0119drzejewska, A. A Review on the neurotoxic effects of doxorubicin. Neurotox. Res. 41, 383\u2013397 (2023).","journal-title":"Neurotox. Res."},{"key":"13496_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202219114","volume":"62","author":"Y Imamura","year":"2023","unstructured":"Imamura, Y., Takaoka, K., Komori, Y., Nagatomo, M. & Inoue, M. Total synthesis of taxol enabled by inter- and intramolecular radical coupling reactions. Angew. Chem. Int. Ed. 62, e202219114 (2023).","journal-title":"Angew. Chem. Int. Ed."},{"key":"13496_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/413076","volume":"2015","author":"NC Kampan","year":"2015","unstructured":"Kampan, N. C., Madondo, M. T., McNally, O. M., Quinn, M. & Plebanski, M. Paclitaxel and Its evolving role in the management of ovarian cancer. BioMed Res. Int. 2015, 413076 (2015).","journal-title":"BioMed Res. Int."},{"key":"13496_CR47","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver, B. A. How taxol\/paclitaxel kills cancer cells. Mol. Biol. Cell 25, 2677\u20132681 (2014).","journal-title":"Mol. Biol. Cell"},{"key":"13496_CR48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3109\/1547691X.2012.655343","volume":"9","author":"A Sevko","year":"2012","unstructured":"Sevko, A. et al. Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J. Immunotoxicol. 9, 275\u2013281 (2012).","journal-title":"J. Immunotoxicol."},{"key":"13496_CR49","doi-asserted-by":"publisher","first-page":"17118","DOI":"10.1074\/jbc.272.27.17118","volume":"272","author":"P Giannakakou","year":"1997","unstructured":"Giannakakou, P. et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272, 17118\u201317125 (1997).","journal-title":"J. Biol. Chem."},{"key":"13496_CR50","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1038\/sj.onc.1209498","volume":"25","author":"T-H Wang","year":"2006","unstructured":"Wang, T.-H. et al. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene 25, 4857\u20134866 (2006).","journal-title":"Oncogene"},{"key":"13496_CR51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ygyno.2005.08.050","volume":"100","author":"E Yakirevich","year":"2006","unstructured":"Yakirevich, E. et al. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol. Oncol. 100, 152\u2013159 (2006).","journal-title":"Gynecol. Oncol."},{"key":"13496_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.bbi.2015.06.003","volume":"49","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy. Brain. Behav. Immun. 49, 255\u2013266 (2015).","journal-title":"Brain. Behav. Immun."},{"key":"13496_CR53","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3390\/ijms23031142","volume":"23","author":"P Montero","year":"2022","unstructured":"Montero, P. et al. Paclitaxel-induced epidermal alterations: An in vitro preclinical assessment in primary keratinocytes and in a 3D epidermis model. Int. J. Mol. Sci. 23, 1142 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"13496_CR54","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10456-013-9334-0","volume":"16","author":"G Bocci","year":"2013","unstructured":"Bocci, G., Di Paolo, A. & Danesi, R. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis 16, 481\u2013492 (2013).","journal-title":"Angiogenesis"},{"key":"13496_CR55","first-page":"31","volume":"14","author":"DH Lau","year":"1999","unstructured":"Lau, D. H., Xue, L., Young, L. J., Burke, P. A. & Cheung, A. T. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm. 14, 31\u201336 (1999).","journal-title":"Cancer Biother. Radiopharm."},{"key":"13496_CR56","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1158\/0008-5472.CAN-06-3914","volume":"67","author":"J Alexandre","year":"2007","unstructured":"Alexandre, J., Hu, Y., Lu, W., Pelicano, H. & Huang, P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res. 67, 3512\u20133517 (2007).","journal-title":"Cancer Res."},{"key":"13496_CR57","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou, T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"issue":"294","key":"13496_CR58","first-page":"302","volume":"41","author":"TT Chang","year":"2000","unstructured":"Chang, T. T. & Chou, T. C. Rational approach to the clinical protocol design for drug combinations: a review. Acta Paediatr Taiwanica Taiwan Er Ke Yi Xue Hui Za Zhi 41(294), 302 (2000).","journal-title":"Acta Paediatr Taiwanica Taiwan Er Ke Yi Xue Hui Za Zhi"},{"key":"13496_CR59","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/ph16040614","volume":"16","author":"V Tateo","year":"2023","unstructured":"Tateo, V. et al. Agnostic approvals in oncology: Getting the right drug to the right patient with the right genomics. Pharmaceuticals 16, 614 (2023).","journal-title":"Pharmaceuticals"},{"key":"13496_CR60","doi-asserted-by":"publisher","first-page":"682872","DOI":"10.3389\/fonc.2021.682872","volume":"11","author":"K Miyabayashi","year":"2021","unstructured":"Miyabayashi, K., Nakagawa, H. & Koike, K. Molecular and phenotypic profiling for precision medicine in pancreatic cancer: Current advances and future perspectives. Front. Oncol. 11, 682872 (2021).","journal-title":"Front. Oncol."},{"key":"13496_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","volume":"9","author":"X-P Duan","year":"2024","unstructured":"Duan, X.-P. et al. New clinical trial design in precision medicine: discovery, development and direction. Signal Transduct. Target. Ther. 9, 1\u201329 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"13496_CR62","doi-asserted-by":"publisher","unstructured":"Zardavas, D. & Piccart-Gebhart, M. Clinical trials of precision medicine through molecular profiling: Focus on breast cancer. Am. Soc. Clin. Oncol. Educ. Book e183\u2013e190 https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.e183 (2015).","DOI":"10.14694\/EdBook_AM.2015.35.e183"},{"key":"13496_CR63","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.chembiol.2022.09.002","volume":"29","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Targeting telomerase reverse transcriptase with the covalent inhibitor NU-1 confers immunogenic radiation sensitization. Cell Chem. Biol. 29, 1517-1531.e7 (2022).","journal-title":"Cell Chem. Biol."},{"key":"13496_CR64","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fcell.2019.00274","volume":"7","author":"Q Zheng","year":"2019","unstructured":"Zheng, Q., Huang, J. & Wang, G. Mitochondria, telomeres and telomerase subunits. Front. Cell Dev. Biol. 7, 274 (2019).","journal-title":"Front. Cell Dev. Biol."},{"key":"13496_CR65","doi-asserted-by":"publisher","first-page":"7582","DOI":"10.3390\/cimb45090478","volume":"45","author":"A Torres-Montaner","year":"2023","unstructured":"Torres-Montaner, A. Interactions between the DNA damage response and the telomere complex in carcinogenesis: A hypothesis. Curr. Issues Mol. Biol. 45, 7582\u20137616 (2023).","journal-title":"Curr. Issues Mol. Biol."},{"key":"13496_CR66","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1007\/s00018-017-2573-2","volume":"74","author":"N Lipinska","year":"2017","unstructured":"Lipinska, N. et al. Telomerase and drug resistance in cancer. Cell. Mol. Life Sci. 74, 4121 (2017).","journal-title":"Cell. Mol. Life Sci."},{"key":"13496_CR67","doi-asserted-by":"publisher","first-page":"2905663","DOI":"10.1155\/2022\/2905663","volume":"2022","author":"W Gu","year":"2022","unstructured":"Gu, W. et al. Research Progress on G-Quadruplexes in human telomeres and human telomerase reverse transcriptase (hTERT) promoter. Oxid. Med. Cell. Longev. 2022, 2905663 (2022).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"13496_CR68","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/nm1006-1133","volume":"12","author":"EH Blackburn","year":"2006","unstructured":"Blackburn, E. H., Greider, C. W. & Szostak, J. W. Telomeres and telomerase: the path from maize, tetrahymena and yeast to human cancer and aging. Nat. Med. 12, 1133\u20131138 (2006).","journal-title":"Nat. Med."},{"key":"13496_CR69","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/nar\/gkr758","volume":"40","author":"NK Sharma","year":"2012","unstructured":"Sharma, N. K. et al. Human telomerase acts as a hTR-independent reverse transcriptase in mitochondria. Nucleic Acids Res. 40, 712\u2013725 (2012).","journal-title":"Nucleic Acids Res."},{"key":"13496_CR70","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/ATVBAHA.109.185546","volume":"29","author":"J Haendeler","year":"2009","unstructured":"Haendeler, J. et al. Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage. Arterioscler. Thromb. Vasc. Biol. 29, 929\u2013935 (2009).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"13496_CR71","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1242\/jcs.019372","volume":"121","author":"S Ahmed","year":"2008","unstructured":"Ahmed, S. et al. Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. J. Cell Sci. 121, 1046\u20131053 (2008).","journal-title":"J. Cell Sci."},{"key":"13496_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052989","volume":"8","author":"C Singhapol","year":"2013","unstructured":"Singhapol, C. et al. Mitochondrial telomerase protects cancer cells from nuclear DNA damage and apoptosis. PLoS ONE 8, e52989 (2013).","journal-title":"PLoS ONE"},{"key":"13496_CR73","doi-asserted-by":"publisher","first-page":"24185","DOI":"10.1038\/s41598-024-75127-4","volume":"14","author":"D Burkatovskii","year":"2024","unstructured":"Burkatovskii, D. et al. Examining transfer of TERT to mitochondria under oxidative stress. Sci. Rep. 14, 24185 (2024).","journal-title":"Sci. Rep."},{"key":"13496_CR74","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-022-04582-8","volume":"604","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Structure of active human telomerase with telomere shelterin protein TPP1. Nature 604, 578\u2013583 (2022).","journal-title":"Nature"},{"key":"13496_CR75","doi-asserted-by":"publisher","first-page":"30565","DOI":"10.1021\/acsomega.2c04082","volume":"7","author":"H Qin","year":"2022","unstructured":"Qin, H. & Guo, Y. Targeting telomerase enhances cytotoxicity of salinomycin in cancer cells. ACS Omega 7, 30565\u201330570 (2022).","journal-title":"ACS Omega"},{"key":"13496_CR76","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1021\/acs.jmedchem.2c01668","volume":"66","author":"AA Al-Karmalawy","year":"2023","unstructured":"Al-Karmalawy, A. A. et al. Ligand-based design on the dog-bone-shaped BIBR1532 Pharmacophoric features and synthesis of novel analogues as promising telomerase inhibitors with in vitro and in vivo evaluations. J. Med. Chem. 66, 777\u2013792 (2023).","journal-title":"J. Med. Chem."},{"key":"13496_CR77","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10245332.2016.1275426","volume":"22","author":"D Bashash","year":"2017","unstructured":"Bashash, D., Zareii, M., Safaroghli-Azar, A., Omrani, M. D. & Ghaffari, S. H. Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells. Hematology 22, 330\u2013340 (2017).","journal-title":"Hematology"},{"key":"13496_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106939","volume":"203","author":"EA Elmorsy","year":"2024","unstructured":"Elmorsy, E. A. et al. Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies. Eur J Pharm Sci. 203, 106939 (2024).","journal-title":"Eur J Pharm Sci."},{"key":"13496_CR79","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/neuonc\/noab203","volume":"23","author":"E Aquilanti","year":"2021","unstructured":"Aquilanti, E., Kageler, L., Wen, P. Y. & Meyerson, M. Telomerase as a therapeutic target in glioblastoma. Neuro-Oncol. 23, 2004\u20132013 (2021).","journal-title":"Neuro-Oncol."},{"key":"13496_CR80","first-page":"243","volume":"1","author":"D La Torre","year":"2011","unstructured":"La Torre, D. et al. Potential clinical role of telomere length in human glioblastoma. Transl Med UniSa. 1, 243\u2013270 (2011).","journal-title":"Transl Med UniSa."},{"key":"13496_CR81","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2008772118","volume":"118","author":"AM Amen","year":"2021","unstructured":"Amen, A. M. et al. Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 118, e2008772118 (2021).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"13496_CR82","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11523-015-0364-y","volume":"10","author":"Y Shi","year":"2015","unstructured":"Shi, Y. et al. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines. Target. Oncol. 10, 565\u2013573 (2015).","journal-title":"Target. Oncol."},{"key":"13496_CR83","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/jcb.27089","volume":"120","author":"F Do\u011fan","year":"2019","unstructured":"Do\u011fan, F. et al. Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells. J. Cell. Biochem. 120, 1282\u20131293 (2019).","journal-title":"J. Cell. Biochem."},{"key":"13496_CR84","doi-asserted-by":"publisher","first-page":"11917","DOI":"10.1007\/s13277-016-5045-7","volume":"37","author":"HA Ceja-Rangel","year":"2016","unstructured":"Ceja-Rangel, H. A. et al. Shorter telomeres and high telomerase activity correlate with a highly aggressive phenotype in breast cancer cell lines. Tumor Biol. 37, 11917\u201311926 (2016).","journal-title":"Tumor Biol."},{"key":"13496_CR85","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3892\/or.2015.4063","volume":"34","author":"M Kammori","year":"2015","unstructured":"Kammori, M. et al. Telomere shortening in breast cancer correlates with the pathological features of tumor progression. Oncol. Rep. 34, 627\u2013632 (2015).","journal-title":"Oncol. Rep."},{"key":"13496_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111550","volume":"139","author":"A Awadasseid","year":"2021","unstructured":"Awadasseid, A., Ma, X., Wu, Y. & Zhang, W. G-quadruplex stabilization via small-molecules as a potential anti-cancer strategy. Biomed. Pharmacother. Biomedecine Pharmacother. 139, 111550 (2021).","journal-title":"Biomed. Pharmacother. Biomedecine Pharmacother."},{"key":"13496_CR87","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4155\/fmc-2015-0017","volume":"8","author":"MK Islam","year":"2016","unstructured":"Islam, M. K., Jackson, P. J., Rahman, K. M. & Thurston, D. E. Recent advances in targeting the telomeric G-quadruplex DNA sequence with small molecules as a strategy for anticancer therapies. Future Med. Chem. 8, 1259\u20131290 (2016).","journal-title":"Future Med. Chem."},{"key":"13496_CR88","first-page":"565","volume":"1","author":"CL Grand","year":"2002","unstructured":"Grand, C. L. et al. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol. Cancer Ther. 1, 565\u2013573 (2002).","journal-title":"Mol. Cancer Ther."},{"key":"13496_CR89","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12943-020-01291-6","volume":"20","author":"SK Madden","year":"2021","unstructured":"Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P. & Mason, J. M. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol. Cancer 20, 3 (2021).","journal-title":"Mol. Cancer"},{"key":"13496_CR90","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/j.1742-4658.2009.07463.x","volume":"277","author":"S Neidle","year":"2010","unstructured":"Neidle, S. Human telomeric G-quadruplex: The current status of telomeric G-quadruplexes as therapeutic targets in human cancer. FEBS J. 277, 1118\u20131125 (2010).","journal-title":"FEBS J."},{"key":"13496_CR91","first-page":"10","volume":"4","author":"B Sm","year":"2023","unstructured":"Sm, B. et al. The liquid biopsy consortium: Challenges and opportunities for early cancer detection and monitoring. Cell Rep. Med. 4, 10 (2023).","journal-title":"Cell Rep. Med."},{"key":"13496_CR92","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3892\/ijo.2024.5629","volume":"64","author":"J Xu","year":"2024","unstructured":"Xu, J., Yu, B., Wang, F. & Yang, J. Xenograft and organoid models in developing precision medicine for gastric cancer (Review). Int J. Oncol. 64, 41 (2024).","journal-title":"Int J. Oncol."},{"key":"13496_CR93","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.21037\/tlcr-20-154","volume":"9","author":"K-G Huo","year":"2020","unstructured":"Huo, K.-G., D\u2019Arcangelo, E. & Tsao, M.-S. Patient-derived cell line, xenograft and organoid models in lung cancer therapy. Transl Lung Cancer Res. 9, 2214 (2020).","journal-title":"Transl Lung Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13496-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:05:19Z","timestamp":1758884719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13496-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13496"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13496-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32958"}}